EyePoint Pharmaceuticals EYPT Stock
EyePoint Pharmaceuticals Price Chart
EyePoint Pharmaceuticals EYPT Financial and Trading Overview
| EyePoint Pharmaceuticals stock price | 4.62 USD |
| Previous Close | 7.03 USD |
| Open | 7 USD |
| Bid | 0 USD x 3200 |
| Ask | 0 USD x 800 |
| Day's Range | 6.73 - 7.2 USD |
| 52 Week Range | 2.19 - 11.44 USD |
| Volume | 337.62K USD |
| Avg. Volume | 907.81K USD |
| Market Cap | 232.91M USD |
| Beta (5Y Monthly) | 1.140492 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.32 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.75 USD |
EYPT Valuation Measures
| Enterprise Value | 159.8M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.6523438 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.853037 |
| Price/Book (mrq) | 2.9715536 |
| Enterprise Value/Revenue | 4.016 |
| Enterprise Value/EBITDA | -1.989 |
Trading Information
EyePoint Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.140492 |
| 52-Week Change | -14.050% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.44 USD |
| 52 Week Low | 2.19 USD |
| 50-Day Moving Average | 5.99 USD |
| 200-Day Moving Average | 4.98 USD |
EYPT Share Statistics
| Avg. Volume (3 month) | 907.81K USD |
| Avg. Daily Volume (10-Days) | 424.8K USD |
| Shares Outstanding | 34.3M |
| Float | 14.85M |
| Short Ratio | 9.09 |
| % Held by Insiders | 10.57% |
| % Held by Institutions | 86.03% |
| Shares Short | 4.26M |
| Short % of Float | 20.26% |
| Short % of Shares Outstanding | 12.41% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -257.43% |
| Operating Margin (ttm) | -206.58% |
| Gross Margin | 57.63% |
| EBITDA Margin | -201.92% |
Management Effectiveness
| Return on Assets (ttm) | -25.74% |
| Return on Equity (ttm) | -83.55% |
Income Statement
| Revenue (ttm) | 39.79M USD |
| Revenue Per Share (ttm) | 1.07 USD |
| Quarterly Revenue Growth (yoy) | -17.29% |
| Gross Profit (ttm) | 26.95M USD |
| EBITDA | -80353000 USD |
| Net Income Avi to Common (ttm) | -102442000 USD |
| Diluted EPS (ttm) | -2.9 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 122.48M USD |
| Total Cash Per Share (mrq) | 3.57 USD |
| Total Debt (mrq) | 41.14M USD |
| Total Debt/Equity (mrq) | 52.48 USD |
| Current Ratio (mrq) | 5.361 |
| Book Value Per Share (mrq) | 2.285 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -61682000 USD |
| Levered Free Cash Flow (ttm) | -34283376 USD |
Profile of EyePoint Pharmaceuticals
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 480 Pleasant Street |
| ZIP | 02472 |
| Phone | 617 926 5000 |
| Website | https://eyepointpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 144 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Q&A For EyePoint Pharmaceuticals Stock
What is a current EYPT stock price?
EyePoint Pharmaceuticals EYPT stock price today per share is 4.62 USD.
How to purchase EyePoint Pharmaceuticals stock?
You can buy EYPT shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for EyePoint Pharmaceuticals?
The stock symbol or ticker of EyePoint Pharmaceuticals is EYPT.
Which industry does the EyePoint Pharmaceuticals company belong to?
The EyePoint Pharmaceuticals industry is Biotechnology.
How many shares does EyePoint Pharmaceuticals have in circulation?
The max supply of EyePoint Pharmaceuticals shares is 68.73M.
What is EyePoint Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
EyePoint Pharmaceuticals PE Ratio is now.
What was EyePoint Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
EyePoint Pharmaceuticals EPS is -2.32 USD over the trailing 12 months.
Which sector does the EyePoint Pharmaceuticals company belong to?
The EyePoint Pharmaceuticals sector is Healthcare.
EyePoint Pharmaceuticals EYPT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1638.71 USD — |
-0.55
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}